

# Development of therapeutic agent for Parkinson's disease targeting alpha synuclein aggregates using autophagy targeting chimera (AUTOTAC)

AUTOTAC Bio Inc.



NEUROSCIENCE	Hit
Product Type	Small molecule
Indication	Parkinson's disease
Target	$\alpha$ -synuclein aggregates
MoA(Mechanism of Action)	Autophagic degradation of $\alpha$ -synuclein aggregates
Competitiveness	<ul style="list-style-type: none"> <li>- AUTOTAC is an first in class drug development platforms based on targeted protein degradation using autophagy lysosome pathway. AUTOTACs are chimeric ligands, consisting of Target-Binding Ligands and Autophagy-Targeting Ligands, which allow simultaneous recognition of both the protein-of-interest and p62, an autophagy receptor.</li> <li>- Thus, we designed AUTOTACs that target <math>\alpha</math>-synuclein aggregates species to develop disease modifying drug for PD.</li> </ul>
Development Stage	Hit
Route of Administration	P.O.